Arrivent Biopharma Inc Stock Price, News & Analysis

ArriVent BioPharma (Nasdaq: AVBP), a clinical-stage biopharmaceutical company, has announced plans for a $75 million public offering of common stock and pre-funded warrants. The company will also grant underwriters a 30-day option to purchase up to an additional 15% of the total securities offered.

The offering will be managed by joint book-running managers Goldman Sachs & Co. LLC, Citigroup, and Guggenheim Securities. ArriVent plans to use the proceeds to support the development of firmonertinib and other pipeline programs, along with working capital and general corporate purposes.

The offering is being conducted through an automatic shelf registration statement on Form S-3ASR filed with the SEC on February 3, 2025. A preliminary prospectus supplement and accompanying base prospectus will be available on the SEC's website.

ArriVent BioPharma (AVBP) reported positive interim data from its Phase 1b FURTHER trial for firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC). The study showed a median progression-free survival of 16.0 months at 240mg dose with significant CNS activity, including 41% complete response rate in CNS evaluable patients. The drug demonstrated 68.2% confirmed overall response rate at 240mg dose with 14.6 months median duration of response. The safety profile remained consistent with EGFR-TKI class drugs, showing manageable side effects. Based on these promising results, ArriVent plans to advance firmonertinib to a global Phase 3 ALPACCA trial, with first patient enrollment expected in H2 2025. The pivotal study is designed to support both accelerated and full approval pathways.

ArriVent BioPharma (Nasdaq: AVBP) has announced a virtual investor event scheduled for June 23, 2025 at 8:00 am ET. The webinar will focus on discussing the clinical program for firmonertinib, their investigational treatment for EGFR PACC mutant non-small cell lung cancer (NSCLC). The event aims to provide investors with insights into the development path and strategy for this therapeutic candidate. ArriVent, a clinical-stage biopharmaceutical company, is focused on accelerating the global development of innovative therapeutics.

ArriVent BioPharma (AVBP) reported its Q1 2025 financial results with significant pipeline progress. The company completed enrollment in its global pivotal Phase 3 FURVENT study for firmonertinib in first-line NSCLC with EGFR exon 20 insertion mutations. ArriVent expanded its pipeline by acquiring ARR-217, a CDH17-targeted ADC for gastrointestinal cancers, through a collaboration with Lepu Biopharma. The company's financial position shows $205.5 million in cash and equivalents, expected to fund operations into H2 2026. Q1 2025 resulted in a net loss of $64.4 million, compared to $17.4 million in Q1 2024, primarily due to a $40 million upfront payment to Lepu Biopharma. R&D expenses increased to $61.3 million, while G&A expenses rose to $5.5 million.

ArriVent BioPharma (Nasdaq: AVBP) has appointed Dr. Merdad Parsey to its Board of Directors. Dr. Parsey, former Chief Medical Officer and Executive Vice President of Gilead Sciences, brings extensive experience in global clinical development within the biopharmaceutical industry.

The appointment comes at a important time as ArriVent advances firmonertinib towards registration and develops its antibody drug conjugate (ADC) pipeline. Dr. Parsey's previous roles include Senior Vice President at Genentech Research and Early Development, CEO of Sagimet Biosciences, and development positions at Sepracor, Regeneron, and Merck.

ArriVent BioPharma (Nasdaq: AVBP) reported its full year 2024 financial results and key milestones. The company achieved target enrollment of 375 patients in its global Phase 3 study of firmonertinib for first-line NSCLC with EGFR exon 20 insertion mutations. Clinical data showed robust responses for firmonertinib in first-line NSCLC EGFR PACC mutations.

Financial highlights include cash and equivalents of $266.5 million as of December 31, 2024, expected to fund operations into 2026. The company reported a net loss of $80.5 million for 2024, compared to $69.3 million in 2023. R&D expenses increased to $79.0 million from $64.9 million in 2023.

Pipeline developments include selecting ADC candidate ARR-002 for IND enabling studies, adding ARR-217 through Lepu Biopharma collaboration, and entering an ADC partnership with Alphamab. The company expects to provide updates on firmonertinib PACC development plans and Phase 3 top-line data timing in 2025.

ArriVent BioPharma (AVBP) has secured an exclusive global license agreement with Lepu Biopharma for MRG007, a novel antibody drug conjugate (ADC) targeting gastrointestinal cancers, for all territories outside Greater China. The deal includes a $47 million upfront and near-term milestone payment, with potential additional payments up to $1.16 billion based on development, regulatory, and sales milestones, plus tiered royalties.

MRG007 has demonstrated strong antitumor activity in preclinical models of GI cancers and favorable therapeutic index in IND enabling studies. The first Investigational New Drug (IND) submission is planned for the first half of 2025, initially focusing on colorectal, pancreatic, and other GI cancers. The company confirms that the agreement's financial terms, including upfront payment and R&D costs, maintain ArriVent's expected cash runway into 2026.

ArriVent BioPharma (Nasdaq: AVBP) reported Q3 2024 financial results with cash and cash equivalents of $282.9 million, expected to fund operations into 2026. The company reported increased R&D expenses of $58.9 million and G&A expenses of $11.8 million for the nine months ended September 30, 2024. Net loss widened to $59.9 million.

The company's lead drug firmonertinib showed positive results in treating NSCLC patients with EGFR PACC mutations, including those with brain metastases. Top-line data from the Phase 3 FURVENT trial for firmonertinib in NSCLC with EGFR exon 20 insertion mutations is expected in 2025.

ArriVent BioPharma (Nasdaq: AVBP) announced positive interim data from its Phase 1b FURTHER trial for firmonertinib in first-line EGFR PACC mutant non-small cell lung cancer (NSCLC) at the 2024 World Conference on Lung Cancer. Key highlights include:

- 81.8% overall response rate (ORR) and 63.6% confirmed ORR at 240mg dose by blinded independent central review (BICR)
- 46.2% confirmed ORR in CNS metastases
- 90.9% of patients with confirmed responses remained on study
- Generally well-tolerated safety profile

Firmonertinib showed promising dose-dependent activity across EGFR PACC mutations and demonstrated CNS antitumor activity. These results suggest potential as an effective oral, chemotherapy-free treatment for this underserved patient population.